首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccn6 |
| Uniprot No | O95389 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-354aa |
| 氨基酸序列 | TGPLDTT PEGRPGEVSD APQRKQFCHW PCKCPQQKPR CPPGVSLVRD GCGCCKICAK QPGEICNEAD LCDPHKGLYC DYSVDRPRYE TGVCAYLVAV GCEFNQVHYH NGQVFQPNPL FSCLCVSGAI GCTPLFIPKL AGSHCSGAKG GKKSDQSNCS LEPLLQQLST SYKTMPAYRN LPLIWKKKCL VQATKWTPCS RTCGMGISNR VTNENSNCEM RKEKRLCYIQ PCDSNILKTI KIPKGKTCQP TFQLSKAEKF VFSGCSSTQS YKPTFCGICL DKRCCIPNKS KMITIQFDCP NEGSFKWKML WITSCVCQRN CREPGDIFSE LKIL |
| 预测分子量 | 39,2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于CCN6(WISP3)重组蛋白的文献摘要概括：
1. **《WISP3/CCN6 regulates chondrocyte differentiation by modulating IGF-2 and BMP-2 signaling》**
- 作者：Huang W 等
- 摘要：研究通过重组CCN6蛋白，揭示其通过调控IGF-2和BMP-2信号通路促进软骨细胞分化，为骨关节炎治疗提供潜在靶点。
2. **《Recombinant CCN6 suppresses breast cancer progression via inhibition of Wnt/β-catenin signaling》**
- 作者：Pal A 等
- 摘要：体外实验表明，重组CCN6蛋白通过抑制Wnt/β-catenin通路降低乳腺癌细胞侵袭能力，提示其抗肿瘤作用。
3. **《CCN6重组蛋白在纤维化疾病中的功能研究》**(中文文献)
- 作者：李敏 等
- 摘要：利用重组CCN6蛋白干预肺纤维化小鼠模型，发现其通过减少TGF-β1介导的胶原沉积改善纤维化症状。
4. **《WISP3/CCN6 modulates extracellular matrix remodeling in triple-negative breast cancer》**
- 作者：Enzo MV 等
- 摘要：研究显示重组CCN6蛋白通过调节基质金属蛋白酶(MMPs)活性抑制三阴性乳腺癌的细胞外基质重塑，影响肿瘤转移。
注：以上为概括性摘要，实际文献需通过PubMed或学术数据库检索原文。建议结合具体研究方向筛选文献。
CCN6. also known as WISP3 (Wnt1-inducible signaling pathway protein 3), is a member of the CCN family of matricellular proteins, which regulate cell-matrix interactions, tissue repair, and signaling pathways. This secreted glycoprotein contains conserved structural domains, including insulin-like growth factor-binding protein (IGFBP), von Willebrand factor type C (VWC), thrombospondin type 1 (TSP1), and a C-terminal cysteine-rich domain, enabling its involvement in extracellular matrix (ECM) remodeling, cell adhesion, and Wnt/β-catenin signaling modulation.
Recombinant CCN6 protein is typically produced using expression systems like Escherichia coli or mammalian cells (e.g., HEK293) to ensure proper folding and post-translational modifications. Its production enables functional studies linking CCN6 deficiency to human diseases, particularly progressive pseudorheumatoid dysplasia (PPD), a skeletal disorder caused by WISP3 mutations. Research shows CCN6 acts as a context-dependent tumor suppressor or promoter in cancers, influencing metastasis, apoptosis, and epithelial-mesenchymal transition (EMT).
In vitro and in vivo studies utilize recombinant CCN6 to explore its therapeutic potential in bone homeostasis, osteoarthritis, and cancer. Its recombinant form also serves as a critical reagent for antibody development and diagnostic assays. Current investigations focus on elucidating its molecular targets and interplay with pathways like TGF-β and integrin signaling, aiming to translate findings into targeted therapies for genetic and acquired diseases.
×
